3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
40
Carcinoma, Non-Small-Cell Lung
32
Colorectal Neoplasms
27
Ovarian Neoplasms
23
Neoplasms
23
Lung Neoplasms
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Pancreatic Neoplasms
17
Leukemia, Myeloid, Acute
16
Head and Neck Neoplasms
16
Lymphoma, Non-Hodgkin
15
Neoplasm Metastasis
14
Fallopian Tube Neoplasms
14
Glioblastoma
13
Esophageal Neoplasms
12
Rectal Neoplasms
11
Lymphoma
11
Squamous Cell Carcinoma of Head and Neck
10
Central Nervous System Neoplasms
10
Carcinoma, Ovarian Epithelial
10
Recurrence
9
Melanoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
9
Leukemia
9
Stomach Neoplasms
8
Prostatic Neoplasms
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Liver Neoplasms
7
Interventions
Vinorelbine
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metatropic dwarfism
×
Drug Therapy
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts